Summary:
Phase2 study for 52 weeks, study comparing the efficacy and safety of Brazikumab to placebo in the treatment of patients with symptoms of moderate to severe Active Ulerative Colitis.
Qualified Participants Must:
• Have diagnosis of Severe Active Ulcerative Colitis
•
Be 16-80 years old
Qualified Participants May Receive:
Study medication for Ulcerative Colitis, Colonoscopies, study supplies, study exams and compensation for time and travel.